|
Multicenter Trial of Prednisone in Alzheimer's Disease Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Multicenter Trial of Prednisone in Alzheimer's Disease conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Multicenter Trial of Prednisone in Alzheimer's Disease Clinical research trials and Multicenter Trial of Prednisone in Alzheimer's Disease medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Multicenter Trial of Prednisone in Alzheimer's Disease. Multicenter Trial of Prednisone in Alzheimer's Disease Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Multicenter Trial of Prednisone in Alzheimer's Disease clinical trial. Participants frequently get the best healthcare available for their Multicenter Trial of Prednisone in Alzheimer's Disease condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "M" Clinical Trials Conditions > Multicenter Trial of Prednisone in Alzheimer's Disease  Multicenter Trial of Prednisone in Alzheimer's Disease
Multicenter Trial of Prednisone in Alzheimer's Disease
For Condition: Alzheimer Disease
Status: Completed
Sponsor(s): National Institute on Aging (NIA) ,
Synopsis: This is a randomized placebo controlled, double blind study. Patients who meet eligibility criteria and decide to participate in the study will be randomly assigned to receive either drug treatment or a placebo. Neither the patients nor the participating investigators will know who is receiving the drugs and who is receiving the placebo. Participation involves 15 outpatient clinic visits over a 68 week period. Patients take study medication at varying doses (the maximum dose is 20 mg daily), along with calcium and vitamin supplements.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Patients with Alzheimer's disease who are in stable medical condition Exclusion Criteria: - Patients with diabetes or severe osteoporosis
Total Enrollment:
Location and Contact Information:
Overall Study Official:
LeonThal, Principal Investigator, University of California, San Diego
University of Minnesota
Minneapolis, Minnesota, 55455
United States
Indiana University Alzheimer's Center
Indianapolis, Indiana, 46202
United States
Mount Sinai Medical Center
New York City, New York, 10029
United States
Washington University
St. Louis, Missouri, 63110
United States
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213
United States
University of California, San Diego
San Diego, California, 92093-0949
United States
Johns Hopkins University
Baltimore, Maryland, 21224
United States
University of Southern California
Los Angeles, California, 90033
United States
Columbia Presbyterian Medical Center
New York City, New York, 11032
United States
University of Kansas Medical Center
Kansas City, Kansas, 66160
United States
University of Texas
Dallas, Texas, 75235-9070
United States
University of Alabama, Birmingham
Birmingham, Alabama, 35294-0017
United States
University of Rochester
Rochester, New York, 14620
United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37212-8646
United States
University of Miami
Miami, Florida, 33140
United States
Mayo Clinic Jacksonville
Jacksonville, Florida, 32225
United States
Burke Medical Research Institute
White Plains, New York, 10605
United States
New York University Medical Center
New York City, New York, 10016
United States
University of South Florida
Tampa, Florida, 33162
United States
Additional Information:
Study ID Numbers: IA0002; 3U01AG10483-08S2
Study Start Date:
Record last reviewed: November 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000178
Other Alzheimer Disease Studies:
1. Multicenter Trial of Prednisone in Alzheimer's Disease
2. Valproate in Dementia (VALID)
3. Bathing persons with Alzheimer's disease aT Home (The BATH Study)
4. The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease
5. Evaluation Of Three Doses of NS 2330 in Patients with Mild to Moderate Dementia of the Alzheimer’s Type
Related Studies:
Other Alzheimer Disease Clinical Trials
Other Alabama Clinical Trials
Other Birmingham Clinical Trials
Multicenter Trial of Prednisone in Alzheimer's Disease
|
|
|
|
|
|
|
|
